Cartherics is a pre-clinical stage company developing cell-based products for the treatment of cancer and other intractable diseases such as endometriosis. Its technology platform is based on gene-edited induced pluripotent stem cells (iPSCs), from which it generates natural killer (NK) cells and other immune cells. Its lead product (CTH-401) is an iPSC-derived NK cell carrying a chimeric antigen receptor (CAR) targeting the tumor associated antigen TAG-72. The CTH-401 cells are also modified by the deletion of two genes to make them less susceptible to immunosuppression. Follow-on CAR-NK cell products targeting tissue factor (TF) are in development. Both TAG-72 and TF are expressed by a range of different types of solid tumors, as well as in endometriosis.

**Meetings with service providers will not be accepted**